Dutch vaccine developer Intravacc has announced that it will continue to develop its pipeline of intranasal vaccines while adding a contract development and manufacturing business. The company said that it will offer GMP manufacturing for clinical trials in addition to R&D services and expects to take on one or two contract projects per year. Intravacc’s pipeline currently includes intranasal vaccines for COVID-19, pertussis, respiratory syncytial virus, and polio.
Intravacc, which started as a government vaccine research institute, became a private company at the beginning of 2021. According to the announcement, the company expects to derive 70-80% of its income from the CDMO portion of the business and about 20% from licensing its proprietary nasal vaccines. The company notes, though, that it is offering its Avacc 10 intranasal vaccine against COVID-19 as open source technology without licensing fees.
Intravacc CEO Jan Groen commented, “Our new hybrid business model makes Intravacc well positioned to capitalize on the rapidly growing market for therapeutic cancer vaccines. Revenues derived from our contract research activities will form the basis of our revenue growth. Our proprietary pipeline of intranasal vaccines is also promising. Intravacc will initiate a financing round, possibly together with a partner, to enable the development of these vaccines up to clinical Phase I.”
Read the Intravacc press release.
Watch an Intravacc video about the Avacc 10 vaccine:
